Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on EGFR tyrosine kinase inhibitor drug Osimertinib resistance in EGFR mutant NSCLC for analysis of immunohistochemistory of tumor tissues.

Next Previous
Trial Profile

Study on EGFR tyrosine kinase inhibitor drug Osimertinib resistance in EGFR mutant NSCLC for analysis of immunohistochemistory of tumor tissues.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Acronyms Study on Osimertinib resistance mechanism

Most Recent Events

  • 29 Nov 2021 Status changed from recruiting to completed.
  • 15 Sep 2020 Status changed from not yet recruiting to recruiting.
  • 09 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top